share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募資說明書
美股SEC公告 ·  08/14 12:43
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with details from their quarterly report filed on the same date. The supplement relates to the resale of up to 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The Quarterly Report attached to the prospectus supplement includes detailed financial information such as a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The report also details the company's reliance on third-party CROs for clinical trials, the risk of which has been highlighted by recent payment difficulties with their CRO for the ASPIRE trial. The company has incurred significant losses since inception and continues to face substantial doubt about its ability to continue as a going concern without additional financing.
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with details from their quarterly report filed on the same date. The supplement relates to the resale of up to 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The Quarterly Report attached to the prospectus supplement includes detailed financial information such as a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The report also details the company's reliance on third-party CROs for clinical trials, the risk of which has been highlighted by recent payment difficulties with their CRO for the ASPIRE trial. The company has incurred significant losses since inception and continues to face substantial doubt about its ability to continue as a going concern without additional financing.
Panbela Therapeutics，Inc.於2024年8月13日提交了一份招股說明書補充，以更新和補充與其於同一日期提交的季度報告相關信息。該補充涉及出售證券持有人最多可轉售4,260,000股普通股。該公司的普通股在OTCQb上以「PBLA」爲標的進行報價，截至2024年8月12日，上報的最後銷售價格爲每股0.35美元。招股說明書附帶的季度報告包括詳細的財務信息，如截至2024年6月30日的六個月內的淨損失爲1430萬美元，現金及現金等價物減少了257.8萬美元至59,000美元。該報告還詳細介紹了該公司在臨床試驗中依賴第三方CROs，並強調了最近ASPIRE試驗的CRO付款困難所帶來的風險。自成立以來，該公司已經遭受了巨額損失，並繼續面臨是否需要額外融資才能繼續經營的重大疑慮。
Panbela Therapeutics，Inc.於2024年8月13日提交了一份招股說明書補充，以更新和補充與其於同一日期提交的季度報告相關信息。該補充涉及出售證券持有人最多可轉售4,260,000股普通股。該公司的普通股在OTCQb上以「PBLA」爲標的進行報價，截至2024年8月12日，上報的最後銷售價格爲每股0.35美元。招股說明書附帶的季度報告包括詳細的財務信息，如截至2024年6月30日的六個月內的淨損失爲1430萬美元，現金及現金等價物減少了257.8萬美元至59,000美元。該報告還詳細介紹了該公司在臨床試驗中依賴第三方CROs，並強調了最近ASPIRE試驗的CRO付款困難所帶來的風險。自成立以來，該公司已經遭受了巨額損失，並繼續面臨是否需要額外融資才能繼續經營的重大疑慮。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息